Prospective subgroup analyses of the randomized MCL‐002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma
暂无分享,去创建一个
E. Campo | S. Pileri | J. Radford | L. Arcaini | M. Trněný | J. Walewski | F. Morschhauser | S. Rule | M. Patturajan | W. Jurczak | D. Belada | T. Lamy | J. Mayer | J. Cabeçadas | Julia Alexeeva | T. Biyukov | Marie‐Laure Casadebaig Bravo
[1] L. Gordon. Faculty Opinions recommendation of Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial. , 2018, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.
[2] M. Ladetto,et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] J. Radford,et al. Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial. , 2016, The Lancet. Oncology.
[4] Nibedita Bandyopadhyay,et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study , 2016, The Lancet.
[5] J. Gribben,et al. Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Michael L. Wang,et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. , 2015, Blood.
[7] A. Goy,et al. Refining the Mantle Cell Lymphoma Paradigm: Impact of Novel Therapies on Current Practice , 2015, Clinical Cancer Research.
[8] J. Drach,et al. Longer‐term follow‐up and outcome by tumour cell proliferation rate (Ki‐67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL‐001(EMERGE) pivotal trial , 2015, British journal of haematology.
[9] B. Coiffier,et al. Effect of prognostic classification on temsirolimus efficacy and safety in patients with relapsed or refractory mantle cell lymphoma: a retrospective analysis , 2015, Experimental Hematology & Oncology.
[10] W. Klapper,et al. Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] H. Kluin-Nelemans,et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] J. Drach,et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] J. Vose,et al. Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] B. Coiffier,et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] I. Lossos,et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma , 2009, British journal of haematology.
[16] Martin Dreyling,et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. , 2006, Blood.
[17] J. Armitage,et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] K. Furuse. [Phase III study]. , 1995, Gan to kagaku ryoho. Cancer & chemotherapy.